Find and Pitch Jounalists, Get Your Story Covered

	Profile	Recent Articles on Subject
1	Alana Hippensteele, Managing Editor Pharmacy Times #pharmacy news, insights. CE provider. Cranbury, New Jersey pharmacyhealthcarejournalism	Advances in the Treatment of Resectable NSCLC: Key Insights From CheckMate 77T, NEOSTAR, and CA209-159 Trials - 5 days ago Embracing a Precision Medicine Approach to KRAS G12C–Mutated Advanced NSCLC With Adagrasib - 6 months ago FDA Approves Tislelizumab-jsgr for Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Prior Chemotherapy - 6 months ago Advancements in HER2+ Breast Cancer Treatment: Insights From the HER2CLIMB-02 Trial - 7 months ago
2	Mike Bassett MedPage Today Explains healthcare complexities. Not endorsements. New York, New York Healthcare journalism	No Survival Gain With Preoperative CRT Plus Perioperative Chemo for Gastric Cancer - 6 days ago Antibody Drug-Conjugate Shows Promising Activity in Extensive-Stage SCLC - 9 days ago Targeted First-Line Combo Approved for EGFR-Mutated Lung Cancer - about 1 month ago Chemotherapy/ICI Combos Falter as Second-Line Treatment for Gastric Cancer - 6 months ago Novel Therapy Promising for Radiation-Induced Oral Mucositis - 7 months ago All-Oral Therapy Promising in Higher-Risk MDS, CMML - 8 months ago Adding Immunotherapy, Anti-TIGIT in First Line Boosts OS in Esophageal Cancer - 8 months ago Oncolytic Virus Shows High Response Rates in BCG-Unresponsive Bladder Cancer - 10 months ago Osimertinib Shows Activity in NSCLC With Uncommon EGFR Mutations - 10 months ago Bispecific Antibody Shows Clinical Activity in Recurrent Ovarian Cancer - 11 months ago RAF/MEK and FAK Inhibitor Combo Effective in Low-Grade Serous Ovarian Cancer - 11 months ago Neoadjuvant Cemiplimab Shows Potential as an Option for Cutaneous SCC - 11 months ago RET Inhibitor Posts Frontline Wins in Medullary Thyroid Cancer, NSCLC - 11 months ago
3	Andrew Joseph STAT News Reporter at STAT. Covers health, medicine in Europe. London, England health reportingmedicine	STAT+: Lung cancer drug from iTeos, GSK shows response, boosting TIGIT as a viable target - 6 days ago
4	Ashley Gallagher, Associate Editor Pharmacy Times One of Cabra girls on GoggleboxIRL. Dublin City, Ireland televisionentertainment	Exploratory Analysis Shows Favorable Outcomes for Amivantamab-Lazertinib Treatment in NSCLC - 8 days ago FDA Approves Amivantamab-Vmjw and Lazertinib for First-Line Treatment of NSCLC - about 1 month ago FDA Grants Orphan Drug Designation to PT217 for Neuroendocrine Carcinoma - about 1 month ago FDA Grants Fast Track Designation to Potential Treatment for Clear Cell Renal Cell Carcinoma - 2 months ago Dostarlimab Plus Chemotherapy Demonstrates Significant Overall Survival Benefit in Endometrial Cancer - 6 months ago FDA Grants Orphan Drug Designation to Tigilanol Tiglate for Soft Tissue Sarcoma - 7 months ago Biosimilar SB8 Is Comparable to Bevacizumab for Non–Small Cell Lung Cancer - 7 months ago FDA Approves Enfortumab Vedotin, Pembrolizumab for Treatment of Urothelial Cancer - 9 months ago Domvanalimab-Containing Regimen Shows Positive Preliminary Data for Upper Gastrointestinal Cancers - 11 months ago
5	Greg Laub MedPage Today Director of Video at MedPage Today. Screenwriter, previous managing editor. videographyscreenwritingediting	Novel TKI Promising in Early Study of HER2-Mutant NSCLC - 3 months ago Adding Tucatinib to T-DM1 Shows PFS Benefit in HER2-Positive Breast Cancer - 9 months ago Novel Doublet Highly Effective in Low-Grade Serous Ovarian Cancer - 10 months ago Ubamatamab Shows Some Activity in Recurrent Ovarian Cancer - 10 months ago Uterine Cancer Trials Made Waves This Year, Experts Say - 10 months ago Anti-TIGIT Drug Fails to Lift Response Rates in Cervical Cancer Trial - 10 months ago
6	Kennedy Ferruggia, Assistant Editor Pharmacy Times #pharmacy news, insights. CE provider. Cranbury, New Jersey pharmacyhealthcarejournalism	Jazz Pharmaceuticals Submits Biologics License Application for Zanidatamab to Treat Biliary Tract Cancer - 6 months ago FDA Approves Pembrolizumab Plus Chemotherapy to Treat Metastatic HER2-Negative Gastric, Gastroesophageal Junction Adenocarcinoma - 10 months ago
7	Ian Ingram MedPage Today Deputy Managing Editor. MedPage Today. New York, New York medical journalismediting	FDA OKs Amivantamab as First-Line Lung Cancer Treatment - 7 months ago JAK1 Inhibitor Shows 'Remarkable' Activity in T-Cell Lymphoma - 9 months ago Menin Inhibitor Yields 63% ORR in Heavily Pretreated Acute Leukemia - 9 months ago New Options Challenge Standard Treatments in EGFR-Mutant NSCLC - 11 months ago
8	Damian Garde STAT News Biotech reporter at STAT. Open to messages. biotechnologyjournalism	Gilead sours on the ‘don’t eat me’ business - 7 months ago
9	Erin Hunter, Associate Editor Pharmacy Times Actor-writer. Nominated BBC Popcorn. London, United Kingdom actingwritingcomedy	Lutetium Lu 177 Dotatate Reduced Risk of Death By 72% Compared to Comparator in Patients With Advanced GEP-NETs - 8 months ago Phase 3 Results Show First-Line Amivantamab-vmjw Plus Chemotherapy Prolongs Survival In Patients With Advanced or Metastatic NSCLC - 8 months ago
10	Aislinn Antrim, Assistant Managing Editor Pharmacy Times Journalist at Pharmacy Times. UNC graduate. PoliticsStorytellingCats	Abemaciclib, NSAI Extend Overall Survival for Patients With Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer - 8 months ago Tucatinib, Trastuzumab Combination Improves Progression-Free Survival in HER2+, Locally Advanced or Metastatic Breast Cancer - 10 months ago New Capivasertib Approval Benefits Patients With Breast Cancer, PIK3CA/AKT1/PTEN Alterations - 10 months ago

Journalists covering gemcitabine